CD274 and non-small cell lung carcinoma: In this issue of the JCI, Hayashi and colleagues (4) evaluated soluble forms of the immune checkpoint molecules PD-L1, PD-1, and CTLA-4 in the plasma of patients with advanced NSCLC who had been treated with anti-PD-1/L1 ICI therapy.